The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aPALACE 1-3 pooled analysis. LOCF; includes patients randomized to OTEZLA 30 mg BID or placebo at baseline.
bData as observed; includes patients who were randomized to OTEZLA 30 mg BID at baseline and remained on treatment for 156 weeks.
cP = 0.0002 vs placebo.
dMCID for BASDAI = -1.1 point improvement.2
During the placebo-controlled period, at week 16, patients taking OTEZLA 30 mg BID achieved a greater mean decrease in BASDAI score vs patients taking placebo (-1.53 vs -0.91; P = 0.0173).1†
*Pooled patient data from PALACE 1-3; BASDAI score was an exploratory measure in the subset of patients with axial symptoms and a baseline BASDAI score of >4 (n=454); BASDAI mean scores at BL were 6.6 for OTEZLA 30 mg BID and 6.4 for placebo.
†LOCF.
BASDAI, Bath Ankylosing Disease Activity Index; BID, twice daily; BL, baseline; LOCF, last observation carried forward; MCID, minimum clinically important difference; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
